thymoma/phosphatase

Lyen an sove nan clipboard la

Chwazi kalite sòt

14 rezilta yo

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the clinical response of oral premalignant lesions to 12-14 weeks of metformin (metformin hydrochloride) intervention. SECONDARY OBJECTIVES: I. Histologic response to metformin intervention in the target lesion. II. Tissue-based biomarkers: metformin effect on

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of taselisib given in combination with enzalutamide: Assessment of dose limiting toxicities (DLTs) during the first 4 weeks of treatment (cycle 1). (Phase Ib) II. To determine the safety and tolerability of taselisib given in

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To evaluate the anti-tumor activity of cabozantinib (XL184) (cabozantinib-s-malate) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with advanced solid tumors including recurrent glioblastoma (GBM). II. To evaluate the overall safety

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. Determine safety, tolerability, feasibility, and the maximum-tolerated dose (MTD) of dose-escalating BYL719 in combination with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer (MBC) after progression on trastuzumab and taxane-based

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To identify the maximally tolerated dose of trametinib to be used in combination with whole brain radiation therapy in patients with brain metastases. (Cohort A) II. To quantify trametinib in resected brain metastatic lesions utilizing high performance liquid

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To assess the anti-tumor activity associated with trametinib monotherapy in patients with triple negative breast cancer (TNBC). SECONDARY OBJECTIVES: I. To assess the anti-tumor activity associated with trametinib in combination with AKT inhibitor GSK2141795 after progression

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the response rate to MK-2206 (Akt inhibitor MK2206), defined as complete response (CR) + partial response (PR). SECONDARY OBJECTIVES: I. To determine response rate to MK-2206 in patients with phosphatase and tensin homolog (PTEN) loss or

Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose of PTX-200 (triciribine phosphate) given on days 1, 8, and 15 every 28 days (maximum of 9 doses) when combined with weekly paclitaxel (80 mg/m^2) for 12 weeks in patients with metastatic breast cancer. (Phase I and Expansion Cohort)

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine whether v-akt murine thymoma viral oncogene (Akt) inhibitor MK2206 achieves objective tumor responses (complete response [CR], partial response [PR]) in advanced breast cancer patients who have a phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) or

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To assess the progression-free survival (PFS) in three separate patient populations with uveal melanoma: Patients on COHORT 1 (guanine nucleotide binding protein [G protein], q polypeptide [Gnaq]/G protein, alpha 11 [Gna11] mutant uveal melanoma; temozolomide [TMZ]/dacarbazine

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To assess the activity of brivanib (brivanib alaninate) for patients with recurrent or persistent endometrial cancer with the frequency of patients who survive progression-free for at least 6 months after initiating therapy or have objective tumor response.. SECONDARY

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the response rate of patients with advanced, persistent, or recurrent endometrial cancer when treated with each of the arms of the trial; the proposed arms are: Arm #1 temsirolimus intravenously (IV) weekly, Arm #2 megestrol (megestrol acetate)/tamoxifen

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the tolerability and maximum tolerated dose of Sorafenib (sorafenib tosylate) when given orally in combination with Bevacizumab in patients with renal cell carcinoma (RCC). (Phase I) II. To estimate the objective response rate of advanced RCC receiving the

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye